[go: up one dir, main page]

WO2022177250A3 - High-purity cancer organoids and construction method therefor - Google Patents

High-purity cancer organoids and construction method therefor Download PDF

Info

Publication number
WO2022177250A3
WO2022177250A3 PCT/KR2022/002183 KR2022002183W WO2022177250A3 WO 2022177250 A3 WO2022177250 A3 WO 2022177250A3 KR 2022002183 W KR2022002183 W KR 2022002183W WO 2022177250 A3 WO2022177250 A3 WO 2022177250A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
organoids
construction method
method therefor
cancer organoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/002183
Other languages
French (fr)
Korean (ko)
Other versions
WO2022177250A2 (en
Inventor
남은지
설향숙
최은혜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Publication of WO2022177250A2 publication Critical patent/WO2022177250A2/en
Publication of WO2022177250A3 publication Critical patent/WO2022177250A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

In order to predict drug responsiveness in cancer patients, it is preferable that cancer organoids reflect the environment of in vivo cancer tissues as it is. However, there is a problem in that while caner organoids are cultured, normal organoids intrude and overgrow, thereby inhibiting the growth of the cancer organoids. The present invention has been devised to solve the above problem and relates to pure cancer organoids not contaminated by normal cells, and a construction method therefor. The cancer organoids according to the construction method of the present invention realizes the in-vivo cancer environment as it is, enabling precise treatment tailored to the patient, whereby the cancer organoids are expected to find great applications in the medicinal field, such as improved prognosis of cancer patients, etc.
PCT/KR2022/002183 2021-02-16 2022-02-16 High-purity cancer organoids and construction method therefor Ceased WO2022177250A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210020489 2021-02-16
KR10-2021-0020489 2021-02-16

Publications (2)

Publication Number Publication Date
WO2022177250A2 WO2022177250A2 (en) 2022-08-25
WO2022177250A3 true WO2022177250A3 (en) 2022-10-13

Family

ID=82931504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/002183 Ceased WO2022177250A2 (en) 2021-02-16 2022-02-16 High-purity cancer organoids and construction method therefor

Country Status (2)

Country Link
KR (1) KR20220117170A (en)
WO (1) WO2022177250A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118773121A (en) * 2024-09-09 2024-10-15 首都医科大学附属北京佑安医院 A humanized liver cancer angiogenesis model and its construction method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170369829A1 (en) * 2015-01-07 2017-12-28 Dana-Farber Cancer Institute, Inc. Microfluidic cell culture of patient-derived tumor cell spheroids
WO2018148208A1 (en) * 2017-02-07 2018-08-16 Corning Incorporated A high throughput 3d assay for immune cell and drug homing, migration and tumor cytotoxicity
KR20190018306A (en) * 2017-08-14 2019-02-22 울산대학교 산학협력단 Method for culturing 3D lung cancer organoid and preparing patient-derived xenograft model using thereof
KR20200144761A (en) * 2019-06-19 2020-12-30 연세대학교 산학협력단 A method for gastric cancer organoid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170369829A1 (en) * 2015-01-07 2017-12-28 Dana-Farber Cancer Institute, Inc. Microfluidic cell culture of patient-derived tumor cell spheroids
WO2018148208A1 (en) * 2017-02-07 2018-08-16 Corning Incorporated A high throughput 3d assay for immune cell and drug homing, migration and tumor cytotoxicity
KR20190018306A (en) * 2017-08-14 2019-02-22 울산대학교 산학협력단 Method for culturing 3D lung cancer organoid and preparing patient-derived xenograft model using thereof
KR20200144761A (en) * 2019-06-19 2020-12-30 연세대학교 산학협력단 A method for gastric cancer organoid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM MINSUH, MUN HYEMIN, SUNG CHANG OAK, CHO EUN JEONG, JEON HYE-JOON, CHUN SUNG-MIN, JUNG DA JUNG, SHIN TAE HOON, JEONG GI SEOK, K: "Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening", NATURE COMMUNICATIONS, vol. 10, no. 1, 1 December 2019 (2019-12-01), XP055823158, DOI: 10.1038/s41467-019-11867-6 *

Also Published As

Publication number Publication date
KR20220117170A (en) 2022-08-23
WO2022177250A2 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
PH12013501790B1 (en) Use of dpp iv inhibitors
UY32177A (en) TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
NZ790449A (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
WO2011026614A3 (en) Compositions and methods for disinfecting materials
WO2018140224A3 (en) Soft tissue fixation device
WO2022177250A3 (en) High-purity cancer organoids and construction method therefor
NZ609594A (en) Eph receptor expression in tumor stem cells
MX351282B (en) Bare metal stent with drug eluting reservoirs having improved drug retention.
AU2012377476A8 (en) Preparation and method for the prophylaxis and treatment of atypical osteoporosis
El Gamel The destructive power of microorganisms: aortic root endocarditis continues to be a threat to the patient and a challenge for the surgeon
Viswanathan et al. Letter to the Editor Regarding the Article" Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care"
Xu et al. Corrigendum to" Micromolar sodium fluoride promotes osteo/odontogenic differentiation in dental pulp stem cells by inhibiting PI3K/Akt pathway"[Archives of Oral Biology 131 (2021) 105265]
CN201328823Y (en) New X-ray examination protector
CN202920670U (en) Pathogenic bacteria disinfector
Zheng et al. Effect of a non-thermal atmospheric pressure argon plasma jet on SOD and MDA levels in oral mucosal ulcer of golden hamsters
Namazi Well-differentiated hand liposarcoma with bone metastases treated successfully with zoledronic acid: a molecular mechanism
Rieger Necrotizing Fasciitis: A Six-Year Experience
UA47981U (en) Method for simultaneous correction of mammary glands in patients with breast cancer using round implants in subcutaneous mastectomy
UA76818U (en) Indrikson's method for stimulating growth of bone callus
Amadasi et al. Prognostic value of clonality analysis in patients with secondary oral squamous cell carcinoma
UA47982U (en) Method for simultaneous correction of mammary glands in patients with breast cancer using anatomic implants in subcutaneous mastectomy
UA53381U (en) method for preparation of an agent with membrane stabilizing action
FR2980973B1 (en) COMPOSITION FOR THE PROPHYLACTIC TREATMENT OF NEUROPATHIC PAIN.
UA105274C2 (en) Indrikson's method for stimulating growth of callus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22756448

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22756448

Country of ref document: EP

Kind code of ref document: A2